Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.25%
0%
-9.25%
6 Months
-24.54%
0%
-24.54%
1 Year
-10.43%
0%
-10.43%
2 Years
-19.02%
0%
-19.02%
3 Years
-26.33%
0%
-26.33%
4 Years
-28.65%
0%
-28.65%
5 Years
-19.67%
0%
-19.67%
Faron Pharmaceuticals Oy for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-6.90%
EBIT to Interest (avg)
-18.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-14.46
EV to EBIT
-12.63
EV to EBITDA
-12.83
EV to Capital Employed
-32.45
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-28.20
-27.90
-1.08%
Interest
2.60
1.40
85.71%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-30.90
-28.70
-7.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -7.67% vs -35.38% in Dec 2022
About Faron Pharmaceuticals Oy 
Faron Pharmaceuticals Oy
Pharmaceuticals & Biotechnology
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.
Company Coordinates 
Company Details
Joukahaisenkatu 6 , TURKU None : 20520
Registrar Details






